Elizabeth Murray is the Executive Director of Global Patient Solutions which includes 127 countries in Africa, Central, South and Southeast Asia, Eastern Europe, Central America and the Caribbean. She joined Gilead Sciences in 2005 as a member of the newly formed National Accounts Management team focused on building and expanding the company’s presence and commitment to people living with HIV disease.
Prior to joining Gilead Sciences, she held several leadership roles. Her ten year tenure at Glaxo Welcome/GlaxoSmithKline began in the early days of the HIV epidemic. Her leadership was a significant contribution to the successful launch and introduction of combination therapy to extend life for people living with HIV. She developed opportunities and models to expand access to care, treatment, disease awareness and medical education in the inner cities and minority, non-English speaking, communities where the burden of disease was and remains disproportionately high and health equity low.
In 2012, the first Medicaid HMO for individuals living with HIV disease was established in Florida, the state with the highest disease burden in the country. In her role as vice president, she established the most successful insurance plan for this population demonstrating a high quality, cost- effective system for increasing access to healthcare to our most vulnerable populations is possible through private-public partnerships.
She later rejoined Gilead to reorganize the company’s Latin America and Caribbean business model and to develop the structure best suited to successfully launch the hepatitis C cure across the region. Today, Gilead has affiliates, country offices, distributors and hybrid business models accelerating access to life saving medicines in this region of 600 million people with the second highest HIV rate after sub-Saharan Africa.
In her current role, she leads a cross-functional and very diverse team focused on driving impact through development and implementation of innovative distribution and patient focused solutions. Her leadership prioritizing efforts to where the needs are greatest continue to drive the company’s mission of making our life-saving medicines available and affordable in resource limited countries. At the close of 2020, more than 20 million people in the developing world had access to treatments for HIV/AIDS, viral hepatitis B and C, and invasive fungal infections made possible through the company’s scientific innovation and Access initiatives. She led the project to make remdesivir for the treatment of COVID19 available through voluntary licensing agreements with 9 generic manufacturing companies based in India, Pakistan and Egypt. Gilead’s transfer of technology and licensing agreements enabled licensed remdesivir treatments for more than 1.25 million people in more than fifty LMICs in a span of six months amidst the pandemic.
Liz has more than 20 years of experience in pharmaceuticals and healthcare delivery and holds a bachelor’s degree in electrical engineering from the University of Miami and a master’s degree in both business administration and industrial engineering. She is fluent in English, Spanish and Portuguese and lives in Miami with her family.